SAB Biotherapeutics (SABS) Total Liabilities (2020 - 2026)

SAB Biotherapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $21.2 million for Q1 2026.

• Quarterly Total Liabilities rose 26.98% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (up 26.98% YoY) and the FY2025 annual result came in at $21.3 million, up 16.95% from the prior year.
• Total Liabilities was $21.2 million for Q1 2026 at SAB Biotherapeutics, roughly flat from $21.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $27.2 million in Q1 2022 and bottomed at $13.1 million in Q3 2023.
• A 5-year average of $19.4 million and a median of $18.4 million in 2025 frame the typical range for Total Liabilities.
• Peak annual rise in Total Liabilities reached 245.4% in 2022, while the deepest fall reached 53.4% in 2022.
• SAB Biotherapeutics' Total Liabilities stood at $19.8 million in 2022, then soared by 34.24% to $26.6 million in 2023, then plunged by 31.59% to $18.2 million in 2024, then climbed by 16.95% to $21.3 million in 2025, then retreated by 0.44% to $21.2 million in 2026.
• Business Quant data shows SABS's Total Liabilities at $21.2 million in Q1 2026, $21.3 million in Q4 2025, and $18.4 million in Q3 2025.